In the present study, the authors compared the long-term risk of nasopharyngeal carcinoma (NPC) of male participants in an NPC multiplex family cohort with that of controls in a community cohort in Taiwan after adjustment for anti-Epstein-Barr virus (EBV) seromarkers and cigarette smoking. A total of 43 incident NPC cases were identified from the 1,019 males in the NPC multiplex family cohort and the 9,622 males in the community cohort, for a total of 8,061 person-years and 185,587 person-years, respectively. The adjusted hazard ratio was 6.8 (95% confidence interval (CI): 2.3, 20.1) for the multiplex family cohort compared with the community cohort. In the evaluation of anti-EBV viral capsid antigen immunoglobulin A and anti-EBV deoxyribonuclease, the adjusted hazard ratios were 2.8 (95% CI: 1.3, 6.0) and 15.1 (95% CI: 4.2, 54.1) for those positive for 1 EBV seromarker and positive for both seromarkers, respectively, compared with those negative for both EBV seromarkers. The adjusted hazard ratio was 31.0 (95% CI: 9.7, 98.7) for participants who reported a family history of NPC and who were anti-EBV-seropositive compared with individuals without such a history who were anti-EBV-seronegative. The findings suggest that both family history of NPC and anti-EBV seropositivity are important determinants of subsequent NPC risk and that the effect of family history on NPC risk cannot be fully explained by mediation through EBV serologic responses.
Familial aggregation of NPC has been widely documented in both Chinese and low-risk populations (6) (7) (8) (9) (10) (11) (12) (13) . Odds ratios for NPC ranging from 4 to 20 have been reported in case-control studies of individuals who reported a first-degree family history of NPC compared with those with no such history (14) (15) (16) (17) (18) (19) (20) (21) (22) . In a complex segregation analysis in China, Jia et al. (23) also reported that multiple genetic and environmental factors likely contributed to the development of NPC. In a population-based cohort study in Greenland and Denmark, the relative risk of NPC was 8.0 (95% confidence interval (CI): 1.1, 3.9) among 766 firstdegree relatives (24) . Familial tendency for NPC may result from genetic and/or environmental risk factors shared by family members.
In our previous studies, both EBV seropositivity and long-term cigarette smoking were found to be associated with an increased NPC risk (25) (26) (27) . EBV seropositivity was found to be more prevalent in family members of NPC cases (28) . Seromarker measurements may reflect EBV infection itself, but they may also reflect an individual's genetic ability to generate high levels of antibodies against EBV or his/her susceptibility to EBV reactivation/ replication. Smoking behavior of an individual may be influenced by parents and siblings (29) . Although the results of many studies have shown a tendency for familial aggregation of NPC, the authors of these studies did not examine EBV status and cigarette smoking simultaneously. Our aim was to evaluate the effect of family history on NPC risk and determine how it might be mediated through other genetically driven or shared environmental risk factors, such as EBV serology or cigarette smoking. To explore this issue, we compared the relative risk of NPC among those with !2 affected family members with that of individuals lacking such a family history, after accounting for serologic EBV patterns and cigarette smoking.
MATERIALS AND METHODS

Cohort recruitment
Community cohort. Details of the study have been published previously (26) . Briefly, study subjects were recruited between 1984 and 1986 from 6 townships in Taiwan. A total of 9,699 males who were !30 years of age participated in our study. Seven were diagnosed with NPC before enrollment in the study, and an additional 67 reported a family history of NPC. These 74 individuals were excluded from this analysis. Each study participant provided written informed consent for an interview, collection of a blood specimen, and an otorhinolaryngologic examination and medical consultation with physicians at the National Taiwan University Hospital. The institutional review board at National Taiwan University approved the study protocol, and informed consent was obtained.
All participants were personally interviewed at local research centers by well-trained research assistants who used a structured questionnaire. The information obtained from the questionnaire interview included sociodemographic characteristics and information on cigarette smoking, alcohol drinking, diet, personal history of sinusitis or other nasal disease, and family history of NPC. Blood samples were collected at the time of enrollment, immediately stored at À30°C, and later tested for antibody titers to 2 EBV antigens associated with NPC: anti-EBV viral capsid antigen (VCA) immunoglobulin A (IgA) and anti-EBV deoxyribonuclease (DNase). We tested for anti-EBV VCA IgA through the use of indirect immunofluorescence assay (30) , and those participants with titers !1:10 were categorized as positive. Anti-EBV DNase antibody levels were evaluated using an enzyme neutralization assay, and those with a result of !2 units of DNase activity were deemed positive. One unit of DNase activity is the amount of enzyme required to convert 1 lg of double-strand DNA into acid-soluble material in 10 minutes at 37°C (31) .
Multiplex family cohort. As described previously, 475 multiplex families were identified from 20,450 NPC cases diagnosed between 1980 and 2003 (28, 32) . A multiplex family was defined as one that had !2 NPC cases among first-, second-, or third-degree adult relatives. Of these, a total of 358 multiplex families, including 2,240 unaffected first-degree relatives (1,104 males and 1,136 females), were enrolled in the study between 1996 and 2004. There were 154 first-degree relatives (84 males and 70 females) for whom incomplete national identification numbers prohibited linkage to national registries and who were therefore excluded from this analysis. In total, 75.9% of the diagnoses of NPC in the 358 multiplex families were confirmed by cross-referencing with the National Cancer Registry, the Death Certificate Registry, and the Chronic Major Disease Registry and/or abstraction of medical charts. For NPC cases diagnosed after the implementation of the National Cancer Registry system in 1979, the confirmation rate was as high as 87.7%. Because we only recruited male subjects in the community cohort, we excluded females from the multiplex cohort, giving us a total of 1,020 male unaffected first-degree relatives. Informed consent was obtained from study subjects. Institutional review boards at both National Taiwan University and the National Institutes of Health approved the study protocol and the informed consent procedure.
All subjects were given a self-administered questionnaire that assessed various risk factors, including socioeconomic status, dietary intake, smoking exposure, occupational history, and alcohol consumption. Biologic samples, including saliva, buccal (mouth) cells, and 35 mL of blood, were obtained for genotyping and EBV antibody testing. Samples were processed within 24 hours and then frozen at À80°C. Serum samples obtained from the blood draw at the time of enrollment in our family study were tested for levels of antibodies to VCA IgA and anti-DNase. EBV testing was performed by the same testing laboratory using the same methods, with cutoff values identical to those used in the above-mentioned community cohort study. For each batch of tests, 1 anti-EBV seronegative serum sample and 1 anti-EBV seropositive serum sample were used for quality control.
with the National Cancer Registry. Linkage was performed for the period between the recruitment date and December 31, 2008. We identified a total of 36 and 11 newly diagnosed NPC cases from the community cohort and multiplex family cohort, respectively. Those subjects with NPC diagnosed within a year of study enrollment were excluded (community cohort: n ¼ 3; multiplex family cohort: n ¼ 1) because those cases were much more likely to be preexisting NPC rather than incident cases.
Statistical analysis
We used the Nelson-Aalen method to estimate the cumulative incidence of NPC among subjects with a family history of NPC (multiplex family cohort members) and those without such a family history (community cohort members) (33) . The Mantel-Haenzel log-rank test was used to compare cumulative incidence curves. The number of personyears of follow-up for each subject was calculated as the time between the date of enrollment and the date of diagnosis of NPC, the date of death, or the date of last link to data from the National Cancer Registry (December 31, 2008), whichever came first. Incidence rates were calculated by dividing the number of incident cases of NPC by the number of person-years of follow-up. Cox's proportional hazards regression analyses were used to assess the univariate hazard ratio of developing NPC with a 95% confidence interval. Adjusted hazard ratio estimates were also calculated after adjustment for various risk factors, including age, ethnicity, years of schooling, anti-EBV seromarkers, cigarette smoking, and family history. The statistical significance for an interaction was tested through the comparison of the likelihood of models with and without the inclusion of an interaction term. The results of anti-EBV VCA IgA and anti-EBV DNase were missing for 53 and 54 individuals, respectively, including 1 NPC case from the community cohort. The results of tests for anti-EBV VCA IgA levels determined by indirect immunofluorescent assay were missing for 263 multiplex family cohort members (including 3 NPC cases) (25.8%) because this particular test was discontinued during the study and replaced by an enzyme-linked immunosorbent assay-based anti-EBV VCA IgA test. The results of anti-EBV DNase tests were missing for 16 individuals (1.6%) from the multiplex family cohort. Cumulative exposure to cigarette smoke was defined in pack-years as the number of packs of cigarettes smoked per day multiplied by the number of years of cigarette smoking. Data on cumulative cigarette smoking were not available for 1 subject from the family cohort and 349 subjects from the community cohort, including 1 NPC case from the community cohort. All statistical tests were 2-tailed.
RESULTS
A total of 1,019 multiplex family cohort members and 9,622 community cohort members were included in this analysis. Table 1 shows the distribution of baseline characteristics among participants in the 2 cohort studies according to age, ethnicity, years of schooling, cigarette smoking status, and anti-EBV seromarkers. Individuals from the multiplex family cohort were younger and more likely to be Fukkienese than were those from the community cohort. Although most of the multiplex family cohort members had !7 years of schooling, nearly 70% of the community cohort members had only 1-6 years of schooling. The prevalence of cigarette smoking was 59.5% in multiplex cohort family members and 64.3% in community cohort members. Seropositivity to anti-EBV VCA IgA was observed among 24.3% of multiplex family cohort members, compared with 1.1% of the community cohort members. The numbers of a Data for ethnicity were not available for 1 participant in the community cohort.
b Data for years of schooling were not available for 203 participants in the community cohort.
c Data for cumulative cigarette smoking were not available for 1 participant in the multiplex family cohort and 349 participants in the community cohort.
d Data for anti-Epstein-Barr virus viral capsid antigen immunoglobulin A tested by using immunofluorescence assay were not available for 263 participants in the multiplex family cohort and 53 participants in the community cohort.
e Data for anti-Epstein-Barr virus deoxyribonuclease were not available for 16 participants in the multiplex family cohort and 54 participants in the community cohort.
individuals who were seropositive for anti-EBV DNase was similar between the 2 cohorts.
The cumulative incidence of NPC is shown in Figure 1 by study cohort (A), anti-EBV seromarkers (B), and cumulative cigarette smoking (C). Members of the multiplex family cohort had a higher cumulative incidence of NPC than did those in the community cohort. Individuals with anti-EBV seropositivity had a higher cumulative incidence of NPC than did those with anti-EBV seronegativity. Smokers with a cumulative cigarette-smoking exposure !30 pack-years had a higher cumulative incidence of NPC than did those with cigarette-smoking exposures <30 pack-years and never smokers. The longer the follow-up duration, the greater were the differences in cumulative NPC incidence. Table 2 shows the incidence rates and adjusted hazard ratios for developing NPC by family history, cumulative pack-years of cigarette smoking, and anti-EBV seromarkers. There were 33 incident NPC cases over a total of 185,587.3 person-years of follow-up in the community cohort and 10 incident NPC cases over a total of 8,060.8 person-years of follow-up in the multiplex family cohort. The mean durations of follow-up were 19.3 and 7.9 years for the community cohort and the multiplex family cohort, respectively. The incidence rates for NPC were 17.8 and 124.1 per 100,000 person-years in the community cohort and the multiplex family cohort, respectively. The NPC incidence in individuals who were seropositive for anti-EBV VCA IgA and/or anti-EBV DNase was higher than that observed in individuals seronegative for both anti-EBV VCA IgA and anti-EBV DNase. Participants with !30 pack-years of cigarette smoking had a higher NPC incidence than did those who smoked for <30 pack-years. Compared with participants in the community cohort, participants in the multiplex family cohort had an adjusted hazard ratio of developing NPC of 11.7 (95% CI: 4.6, 29.9) after adjustment for age, ethnicity, and years of schooling. After further adjustment for anti-EBV seromarkers and cumulative packyears of cigarette smoking, the NPC risk remained significantly higher for members of the multiplex family cohort than for community cohort members (adjusted hazard ratio ¼ 6.8, 95% CI: 2.3, 20.1). Compared with those individuals who were seronegative for anti-EBV VCA IgA, those who were seropositive for anti-EBV VCA IgA had a hazard ratio for 11.6 (95% CI: 4.7, 28.6) after adjustment for age, ethnicity, and years of schooling. Compared with those who were seronegative for anti-EBV DNase, those who were seropositive had a hazard ratio of 3.4 (95% CI: 1.7, 6.6) after adjustment of age, ethnicity, and years of schooling. After further adjustment for family history and cumulative cigarette smoking, the adjusted hazard ratio for developing NPC was 2.8 (95% CI: 1.3, 6.0) for participants who were seropositive for only 1 anti-EBV seromarker and 15.1 (95% CI: 4.2, 54.1) for those who were seropositive for both anti-EBV seromarkers compared with participants who were seronegative for both anti-EBV seromarkers. Although a residual increase in risk was observed for cumulative pack-years of cigarette smoking after adjustment for family history and anti-EBV seromarkers, the effect was not statistically significant (P ¼ 0.16).
The association with NPC for the combination of family history, anti-EBV seromarkers, and cumulative pack-years of cigarette smoking after adjustment for age, ethnicity, and years of schooling was further evaluated. As shown in Table 3 , no evidence for departure from a multiplicative model was observed for any of the joint effects evaluated. Of interest is the fact that individuals with a family history of NPC who were also seropositive for anti-EBV seromarkers had an adjusted hazard ratio of 31.0 (95% CI: 9.7, 98.7) compared with individuals with no family history of NPC who were anti-EBV seronegative.
DISCUSSION
To our knowledge, this is the first prospective study to evaluate the association between family history and NPC risk after accounting for anti-EBV seromarkers and cigarette smoking. The study utilized data from 2 cohort studies comprising over 10,000 individuals. The longitudinal design minimized recall bias concerns related to the ascertainment of NPC family history and exposure to environmental risk factors. We also avoided issue of causal temporality by assessing EBV serostatus at study entry, which meant that measurements occurred on average 10.2 years before diagnosis in cases. Subjects were identified via linkage to a longstanding population-based national tumor registry.
There are some considerations to our study. First, the 2 cohorts were recruited at different times (1980s versus the late 1990s). NPC diagnostic methods may have changed over time. However, the overall incidence of NPC in Taiwan was stable in the 1980s and 1990s (34) . Second, individuals from the multiplex family cohort might have been more concerned with health than those from the community cohort. However, because persons with NPC are unlikely to remain symptom-free and because Taiwan has a national health care system with broad access, it is expected that nearly all NPC cases would ultimately be identified and reported to the National Cancer Registry. Third, there were some differences in the collection of data through structured questionnaires, the temperatures for biospecimen storage, and the response rates between 2 study cohorts. The questionnaire information was collected by personal interview for the community cohort and by self-administration for the multiplex family cohort. Although the collection methods differed, the questions about sociodemographic characteristics and cigarette smoking habits were simple and easy to answer. The storage temperatures for biopsecimens collected from the community and multiplex family cohorts were À30°C and À80°C, respectively. However, researchers tested for anti-EBV seromarkers within 3 months of recruitment, and therefore the difference in storage temperatures would not have affected the test results of anti-EBVs. Although the response rate in the multiplex family cohort was higher than in the community cohort, the cohorts were representative samples of multiplex families and community residents, respectively. Furthermore, the ascertainment of newly developed NPC through data linkage with the National Cancer Registry was exactly the same for both cohorts. Limitations of our study included the small number of newly developed NPC cases resulting from the low incidence of NPC. However, despite this limitation, we were able to observe a statistically significant association between family history of NPC and NPC risk, which was consistent with findings from previous studies (14) (15) (16) (17) (18) (19) (20) (21) (22) 24) . Although it was interesting to evaluate the joint effects of family history and anti-EBV seromarkers, it was difficult to draw any definitive conclusions because of the small numbers of NPC cases. Another potential limitation of our study is that anti-EBV VCA IgA results using the indirect immunofluorescent assay test were available for only 75% of individuals enrolled in the multiplex family cohort. It is reassuring to note, however, that participants with missing anti-EBV VCA IgA data were similar to those for whom data were not missing with respect to all exposure variables (age, ethnicity, educational level, smoking status, and anti-EBV DNase) evaluated in this analysis. Lastly, the anti-EBV seromarker tests were done in the same laboratory at different times.
The magnitude of risk associated with a family history of NPC in our study was higher than that reported in most previous studies (adjusted hazard ratio ¼ 11.7) (14) (15) (16) (17) (18) (19) (20) (21) (22) 24) . The most likely explanation for this difference is our requirement that members of our family cohort report at least 2 family members affected with NPC (i.e., multiplex families). In contrast, other studies considered individuals with !1 relatives affected with NPC. Our findings are therefore generalizable only to individuals who report at least 2 family members with NPC. In this group, our results suggest that unaffected individuals from NPC multiplex families with putatively higher genetic risk might be at greatly elevated risk of NPC. In our study, the hazard ratio for family history declined from 11.7 to 6.8 after adjustment for EBV seromarkers and cigarette smoking. The hazard ratio for seropositivity to anti-EBV VCA IgA and anti-EBV DNase also declined from 23.4 to 15.1 after adjustment for family history and cigarette smoking. In both instances, however, significant residual effects were noted after adjustment. In contrast, the effect of cigarette smoking was no longer significant after we controlled for family history and EBV seropositivity. The effect of family history might theoretically be mediated through common genetic and/or environmental factors shared by family members, such as EBV seroreactivity and cigarette smoking. The fact that family history of NPC remained a significant risk factor after we controlled for these factors, however, suggests that familial aggregation in cigarette smoking behavior and in EBV exposure and/or antibody responses were unlikely to fully explain why individuals with a family history of NPC were at an increased risk of developing NPC themselves. In fact, based on our data, we estimated that approximately 28% of the risk of NPC associated with family history could be explained by EBV (35) . It should be noted that in our study, we did not directly measure the level of EBV exposure. Rather, serologic responses to EBV, as determined by antibody levels detected in circulation, were used as a proxy for the degree of EBV exposure. To the extent that antibody production has an underlying host (e.g., genetic susceptibility) and exogenous determinants (e.g., degree of EBV exposure determined by frequency of reactivation of latent EBV infections), our study was not capable of differentiating between these different components.
To our knowledge, we are the first to evaluate the joint effect of family history of NPC, anti-EBV seromarkers, and cigarette smoking on NPC risk in a prospective manner. We found that both NPC family history and anti-EBV seropositivity were important determinants of subsequent NPC risk and that the effect of family history on NPC could not be fully explained by mediation through EBV serologic responses.
